ELGX - エンドロジックス (Endologix Inc.) エンドロジックス



symbol ELGx
会社名 Endologix Inc. (エンドロジックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 エンドロジックス(Endologix Inc.)は大動脈疾患治療用の医療機デバイスの開発、生産、マーケティング、販売を行う会社である。同社の製品は腹部大動脈瘤(AAA)を治療するために開発された。AAA製品は伝統的な低侵襲的血管内修復(EVAR)または血管内シーリング(EVAS)を含む二つのプラットフォームうちの一つで構築され、二つの血流内腔を通る血流を維持しながら動脈瘤嚢を密封するためのソリューションである。EVAR製品はEndologix AFX血管内AAAシステム、VELA近位エンドグラフト(VELA)、Intuitrak PowerlinkとIntuitrak Deliveryシステム(Intuitrak)を含む。EVAS製品はNellix EndoVascular動脈瘤シールシステム(Nellix EVASシステム)を含む。同社は適合するガイドワイヤー、スネア、およびカテーテル導入シースなどを含むそのEVAR製品の最適な配達を促進するアクセサリーを提供する。   エンドロジックスは米国で医療機器を開発、製造、販売。「AFX」、「パワ―リンク」、「インチュイトラック」、「VERAプロキシマル・エンドグラフト」のブランド名で腹部大動脈瘤の治療用の低侵襲内修復システム、血管閉鎖システム、遠位大動脈人工血管を提供。米国、欧州、日本、南米で製品を販売。   Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA.
本社所在地 2 Musick Irvine CA 92618 USA
代表者氏名 Daniel T. Lemaitre ダニエル・T・レマイトレ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 949-598-4741
設立年月日 33664
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 675人
url https://endologix.com/
nasdaq_url https://www.nasdaq.com/symbol/elgx
EBITDA EBITDA(百万ドル) -36.75600
終値(lastsale) 1.51
時価総額(marketcap) 127681409.75
時価総額 時価総額(百万ドル) 135.53160
売上高 売上高(百万ドル) 177.01300
企業価値(EV) 企業価値(EV)(百万ドル) 330.61360
当期純利益 当期純利益(百万ドル) -72.03700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Endologix Inc. revenues decreased 5% to $87M. Net loss increased 16% to $43.6M. Revenues reflect United States segment decrease of 5% to $59.4M. Higher net loss reflects General and Administrative Expenses increase of 56% to $22.5M (expense) Change in fair value of contingent consi increase from $2.6M (income) to $700K (expense).



   Endologix Files for Chapter 11 Bankruptcy With Deal to be Acquired by Deerfield  2020/07/06 10:39:00 The Wall Street Journal
Endologix Inc. said it has filed for chapter 11 bankruptcy with a deal in hand to be acquired by its biggest lender, health-care investment firm Deerfield Management.
   Endologix Announces Departure of CFO and Appointment of Interim CFO  2020/06/18 20:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob, Chief Financial Officer (CFO), will be departing the Company effective July 1, 2020 to become CFO of a private global healthcare company. Cindy Pinto, Vice President, Financial Planning & Analysis, will assume the role of interim Chief Financial Officer in addition to her current responsib
   Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft System  2020/06/15 20:01:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Endologix® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued for the Ovation iX system, that identifies the root cause of polymer leaks. This voluntary action has been classified by the FDA as a Class 1 recall. No physical product removal of the product is planned or needed. Correction Z-2263-2020 was issued in May 2020 to current us
   COVID-19 Impact and Recovery Analysis- Aortic Stent Grafts Market 2020-2024 | Rising Preference for EVAR to Boost Growth | Technavio  2020/06/11 01:40:00 Benzinga Feeds
Technavio has been monitoring the aortic stent grafts market and it is poised to grow by USD 690.09 million during 2020-2024, progressing at a CAGR of over 5% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200610005672/en/ Technavio has announced its latest market research report titled Global Aortic Stent Grafts Market 2020-2024 (Photo: Business Wire). Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Request for Technavio's latest reports on directly and indirectly impacted markets. Market estimates include pre- and post-COVID-19 impact on the Aortic Stent Grafts Market Download free sample report The market is concentrated, and the degree of concentration will accelerate during the forecast period.
   9th Circuit rejects stock-drop claims against device withdrawn from FDA approval  2020/06/10 22:24:31 Reuters
A federal appeals court has affirmed the dismissal of a proposed class action lawsuit accusing medical device maker Endologix Inc and its executives of concealing serious problems with its Nellix aneurysm sealing device from investors, resulting in a sharp stock drop when it revealed the product would not receive FDA approval.

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 エンドロジックス ELGX Endologix Inc.)


 twitter  (公式ツイッターやCEOツイッターなど)